BioCryst Pharmaceuticals (BCRX) is at a pivotal moment, transitioning from clinical-stage to commercial success. Its flagship product, Orladeyo, treats hereditary angioedema (HAE).
In Q4 2025, Orladeyo sales reached approximately $151 million, meeting expectations. Full-year 2025 Orladeyo revenue is projected at $590-$600 million.
2026 sales guidance of $625-$645 million implies 13% year-over-year growth. The company expects non-GAAP profitability in 2026.
In December 2025, the FDA approved Orladeyo for children aged 2-11 with HAE, making it the first oral therapy for this age group. This addresses a critical unmet need and creates a competitive moat.
The pediatric market adds about $100 million in revenue potential with minimal additional investment since clinical trials are complete.
BioCryst ended 2025 with $388 million in cash. The gross profit margin stands at 76.6%.
Beyond Orladeyo, BioCryst is developing BCX17725, a KLK5 inhibitor for Netherton syndrome. First patient data is expected by end of 2026.
Long-term revenue target is $1.8 billion by 2033, driven by Orladeyo growth, geographic expansion, and pipeline assets.
